Artivion (AORT) Wins FDA Approval, Is The Stock Still 53% Undervalued?
Artivion (AORT) recently received FDA premarket approval for its AMDS Hybrid Prosthesis, a move that has drawn significant attention to the stock. Despite a 19.14% increase in the last 30 days, the share price is still down 46.09% year-to-date and trades significantly below its US$42 analyst target and a calculated fair value of $51.57, suggesting it could be substantially undervalued. However, the company's high P/E ratio of 99.6x, compared to the industry average of 26.5x, indicates that much optimism is already priced in, leading to diverging views on its future potential.
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth
Artivion has increased its 2025 revenue guidance to $435 million–$443 million, driven by strong double-digit growth in its On-X heart valve and stent graft product lines. The company also reported Q4 2023 revenue of $85.6 million and full-year 2023 revenue of $334.2 million, surpassing previous expectations. This positive outlook reflects the company's successful financial performance and product segment strength.
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospitals and capitalize on an estimated $150 million annual market opportunity. The AMDS device, supported by data showing reduced mortality and adverse events, reinforces Artivion's competitive position in the aortic disease market.
Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell
Artivion (AORT) announced that its AMDS hybrid prosthesis device has received U.S. Food and Drug Administration (FDA) premarket approval. The device is designed to treat thoracoabdominal aortic aneurysm (TAAA) disease. Following the announcement, shares of Artivion were up over 7% in pre-bell trading.
Enterprise value to revenue forward of Artivion, Inc. – SWB:CYL
This article provides financial information for Artivion, Inc. (SWB:CYL) on the Stuttgart Stock Exchange. It specifically highlights the enterprise value to revenue forward metric for the company. The content appears to be a financial data point or a brief note from a financial platform like TradingView.
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion Inc. received FDA approval for its AMDS Hybrid Prosthesis, which treats acute DeBakey Type I aortic dissections, removing previous institutional review board requirements and easing access for hospitals. This approval validates clinical benefits observed in the PERSEVERE study and opens a $150 million annual market opportunity in the U.S. for Artivion, enhancing their portfolio of aortic arch solutions.
AORT - Artivion Inc Options
This article provides an overview of Artivion Inc. (AORT) stock options, displaying key financial metrics and performance indicators as of June 30, 2026. It includes data on market capitalization, earnings, sales, insider and institutional ownership, and various price performance metrics. The information is presented in a data-rich format for investors and analysts.
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis
Artivion (AORT) shares rose 17.3% after receiving full FDA premarket approval for its AMDS Hybrid Prosthesis for acute DeBakey Type I aortic dissections, eliminating the need for prior hospital IRB approval. This approval validates the device's trial data, which showed significant reductions in early mortality and major adverse events, and opens up an estimated US$150 million annual U.S. market. While the FDA approval is positive, the article also notes potential risks such as product concentration, premium valuation, and the impact of the company's recent removal from several Russell indexes.
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion (NYSE: AORT) has received FDA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the need for institutional review board approval, streamlining access for U.S. hospitals and patients. The company estimates a $150 million annual market opportunity in the U.S. for the device, which demonstrated significant reductions in mortality and major adverse events in clinical trials.
Artivion Shares Rise After FDA Approves AMDS Aortic Device
Artivion Inc. (NYSE: AORT) saw its shares rise after the FDA approved its AMDS Hybrid Prosthesis for treating acute DeBakey Type I aortic dissections, particularly those involving malperfusion. This approval removes the need for institutional review board authorization, broadening market access. The company estimates this creates a $150 million annual market opportunity in the U.S., supported by clinical data showing significant reductions in mortality and major adverse events compared to standard procedures.
Artivion Wins FDA Nod for AMDS Hybrid Prosthesis
Artivion has received U.S. FDA approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This device is the first aortic arch remodeling device for this condition and has shown significant reductions in mortality and major adverse events in clinical trials. The approval is expected to accelerate the adoption of this life-saving technology and further establishes Artivion's comprehensive portfolio of aortic arch solutions.
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index
Artivion, Inc. (NYSE: AORT), a medical device company specializing in aortic diseases, has been removed from the Russell Microcap Value Benchmark Index. This news follows several other recent index removals for Artivion from benchmarks such as the Russell 2000 Defensive Index, Russell 2000 Value Benchmark, Russell 3000E Index, and Russell Microcap Index. The company has a diverse product portfolio including aortic stent grafts, mechanical heart valves, and surgical sealants.
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections
Artivion (NYSE:AORT) has received U.S. FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections with malperfusion. This approval eliminates HDE-related institutional review board requirements and is supported by data from the PERSEVERE trial. The company estimates this indication represents an annual U.S. market opportunity of approximately $150 million.
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion, Inc. announced that the U.S. FDA has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device for treating acute DeBakey Type I aortic dissections. This approval removes the previous requirement for hospitals to obtain IRB approval, facilitating broader and more immediate use of the device. The AMDS has shown significant reductions in mortality and major adverse events, addressing a critical need in treating this life-threatening condition.
Price to earnings forward of Artivion, Inc. – NYSE:AORT
This page provides financial data for Artivion, Inc. (NYSE: AORT), specifically focusing on its forward price-to-earnings ratio. The content is presented within the TradingView platform, offering an overview of the company's financials for investors and traders.
Artivion, Inc. Actuals & Estimates (NYSE:AORT)
This article provides an overview of Artivion, Inc. (AORT) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, upcoming earnings reports, and financial metrics such as revenue, net income, and EBITDA, while clarifying that AORT does not pay dividends.
AORT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Artivion, Inc. (AORT) stock, including analyst price targets, historical performance, and key financial metrics. According to 8 analysts, AORT has a max price estimate of $48.00 and a min estimate of $36.00. The article also details the company's recent stock performance, earnings, revenue, and market capitalization, along with its next earnings report date.
Artivion Inc (AORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Artivion Inc (AORT), showing its performance by business segment and geographical region. As of the latest update (Mon, Apr 6), the company's major revenue contributors are Aortic stent grafts, On X, and Preservation Services, with International sales slightly surpassing those in the United States. The data presented covers financial years up to FY2025 relevant quarters.
Artivion’s Andrew Green sells $910,738 in company stock
Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold company common stock totaling $910,738 on June 11, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved 44,001 shares at weighted average prices between $20.694 and $20.707. Prior to these sales, Green acquired the same number of shares by exercising stock options valued at $589,078.
Artivion’s Andrew Green sells $910,738 in company stock
Andrew M. Green, SVP of Regulatory and Quality at Artivion, Inc. (NASDAQ:AORT), sold 44,001 shares of company common stock worth $910,738. These transactions occurred on June 11, 2026, under a pre-arranged Rule 10b5-1 trading plan, following his acquisition of the same number of shares through stock option exercises for $589,078. The sales took place while Artivion's stock was trading near $20.62, representing a 56% decline from its 52-week high, despite analysts maintaining price targets suggesting significant upside.
Artivion’s Andrew Green sells $910,738 in company stock By Investing.com
Andrew M. Green, SVP of Regulatory and Quality at Artivion (NASDAQ:AORT), sold 44,001 shares of company stock for $910,738 on June 11, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he acquired the same number of shares through stock option exercises for $589,078. The stock trades near $20.62, representing a 56% decline from its 52-week high, despite analysts setting price targets between $36 and $48.
Artivion (AORT) SVP exercises options and sells 44,001 shares under 10b5-1 plan
Artivion, Inc. (AORT) Senior Vice President Andrew M. Green executed a pre-arranged transaction under a Rule 10b5-1 trading plan, exercising stock options for 44,001 shares and subsequently selling all of these shares in open-market transactions. The sales occurred on June 11, 2026, at weighted average prices of approximately $20.694 and $20.707 per share. Following these transactions, Green directly retained 60,259 shares of Artivion common stock.
Precision Trading with Artivion Inc Com (AORT) Risk Zones
This article analyzes Artivion Inc Com (AORT) with a focus on risk zones and trading strategies developed by AI models. It identifies a near-term neutral sentiment but suggests weakness in the mid and long term, highlighting elevated downside risk. The article provides specific strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Precision Trading with Artivion Inc Com (AORT) Risk Zones
The article provides a detailed analysis of Artivion Inc Com (AORT) using AI models to identify risk zones and potential trading strategies. It highlights a near-term neutral sentiment but suggests weakness in the mid and long term, with elevated downside risk. Three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—are outlined with specific entry, target, and stop-loss levels.
What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders
Artivion (AORT) reported strong 17.5% year-over-year revenue growth in Q1 2026 to US$116.3 million but missed analyst EPS estimates and slightly reduced its full-year guidance. This mixed performance highlights the company's growth momentum alongside challenges in profitability and execution. The article suggests that while new product approvals like the NEXUS Aortic Arch System offer growth potential, investors must consider pricing pressures and operational complexities.
[144] ARTIVION, INC. SEC Filing
This article is an SEC Form 144 filing for Artivion, Inc. (AORT), indicating a proposed sale of securities. The filing details the securities to be sold, including 44,001 common shares with an aggregate market value of $910,752.99, acquired through a stock option exercise, and notes that no securities were sold in the past three months.
Cardiac surgery company Artivion joins 2026 Truist MedTech conference in Boston
Artivion (NYSE: AORT), a leading cardiac and vascular surgery company, announced its participation in the 2026 Truist Securities MedTech Conference. The company will host a fireside chat on June 16, 2026, at the Boston Harbor Hotel, which will also be available via a live webcast on its investor relations website. This event offers insight into Artivion's focus on developing solutions for aortic diseases and its product lines, including aortic stent grafts, surgical sealants, and heart valves.
Will Stronger Revenue but Softer Outlook Change Artivion's (AORT) Growth-Quality Narrative?
Artivion (AORT) recently reported a 17.5% year-on-year revenue increase, but analyst EPS estimates were missed, and full-year revenue guidance was slightly lowered. This combination of strong revenue growth and a trimmed outlook prompts a re-evaluation of Artivion's investment narrative, focusing on execution, profitability, and debt load despite long-term growth projections. The revised guidance of US$480 million to US$496 million for 2026 highlights a tension between near-term performance and the company's growth strategy for premium products.
Artivion to Participate in the 2026 Truist Securities MedTech Conference
Artivion, Inc. announced its participation in the 2026 Truist Securities MedTech Conference on June 16, 2026, where it will host a fireside chat. A live webcast of the event will be available on Artivion's website. The company specializes in medical devices for cardiac and vascular surgery, focusing on aortic diseases, and markets its products globally.
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
This article analyzes the Q1 earnings of several medical device and supplies companies focusing on cardiology, neurology, and vascular care. Artivion (NYSE:AORT) reported revenue growth but missed EPS estimates and its stock dropped significantly. ICU Medical (NASDAQ:ICUI) outperformed with strong revenue and EPS beats, while Penumbra (NYSE:PEN) and Merit Medical Systems (NASDAQ:MMSI) had mixed results with some beats and misses against analyst expectations, leading to modest stock declines.
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
This article examines the Q1 earnings performance of several medical devices and supplies companies, focusing on the cardiology, neurology, and vascular sectors. It highlights Artivion (NYSE:AORT) as having the weakest Q1 performance against analyst estimates, despite revenue growth, leading to a significant stock drop. In contrast, ICU Medical (NASDAQ:ICUI) is identified as the best performer, beating analyst expectations and seeing its stock rise.
Artivion (AORT) Q1 2026 Earnings: Revenue Growth of 17.5% Meets Expectations Amid Mixed Industry Results
Artivion (AORT) reported a 17.5% year-over-year revenue increase to $116.3 million in Q1 2026, matching analyst expectations, amidst a mixed performance for the medical device and supply sector. Despite the revenue match, the quarter was characterized by a shortfall in analyst EPS estimates and slightly missed full-year revenue guidance. The company's growth was driven by strong performances in stent grafts, On-X, preservation services, and BioGlue.
Artivion (AORT) SVP discloses common stock, RSU and option holdings
Andrew M. Green, Senior Vice President of Regulatory and Quality at Artivion, Inc. (AORT), has filed an initial ownership report detailing his holdings. The report indicates he holds 60,259 shares of common stock, which includes 41,529 restricted stock units, and stock options for an additional 44,001 shares with varying exercise prices and expiration dates in 2029. This Form 3 filing serves as an initial disclosure of his beneficial ownership and does not represent new buying or selling activity.
Estate move: Artivion (AORT) director moves 6,325 shares into trust
Artivion (AORT) director Anthony B. Semedo transferred 6,325 common shares from his direct holdings to the Stacie Nelson and Anthony Semedo Living Trust on June 2, 2026, for estate planning purposes. This transaction did not involve a sale for value and only changed the form of ownership from direct to indirect. Following the transfer, Semedo directly holds 40,635 shares, while 6,325 shares are held indirectly through the trust, and an additional 600 shares are held indirectly through his spouse.
Stifel reiterates Artivion stock rating on surgeon survey results
Stifel reiterated a Buy rating and $45.00 price target for Artivion Inc. based on a survey of aortic and cardiothoracic surgeons. The survey focused on the company's AMDS device, which despite lower-than-expected adoption reported in Q1 2026 earnings, is being integrated into real-world surgical practice. Surgeons predict utilizing AMDS for about 32% of ATAAD procedures, with longer-term data being a key growth driver, even as Artivion shares are down significantly year-to-date.
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $36 to $48
This article provides an overview of current analyst ratings for Artivion (AORT.US), indicating a forecast share price range of $36 to $48. It summarizes the latest analyst perspectives and price targets for the medical device company.
Stifel reiterates Artivion stock rating on surgeon survey results By Investing.com
Stifel maintained a Buy rating and $45 price target for Artivion (NYSE:AORT) after a surgeon survey regarding its AMDS device indicated successful integration into surgical practice. Despite a recent reduction in full-year guidance and an approximately 50% year-to-date stock decline, the survey suggests AMDS is being adopted, with potential for increased market share. The company also recently completed the acquisition of Endospan Ltd. for $135 million, aiming to expand its endovascular solutions.
AORT Financials: Revenue Breakdown, Margins & Competitor Comparison
Artivion Inc (AORT) generates its revenue primarily from Aortic stent grafts, which account for 34.9% of total sales. The company demonstrates strong profitability with a gross margin of 64.85%, an operating margin of 3.51%, and a net margin of 1.22%. AORT competes with industry leaders like CDNA and CNMD, holding a significant market capitalization of $1.08B.
Artivion secures FDA approval for NEXUS aortic arch system
Artivion, Inc., a medical device company, has received FDA approval for its NEXUS Aortic Arch System. This approval will allow Artivion to launch the device in the U.S. during the third quarter of 2026. The NEXUS system offers an off-the-shelf solution for total aortic arch repair, aiming to simplify complex procedures and expand treatment options for patients.
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition
Artivion has announced FDA approval for its NEXUS aortic arch device, making it one of the few companies with a device cleared for this part of the aorta. This approval expands the company's treatment options for complex aortic disease. Additionally, Artivion is evaluating a potential acquisition of Endospan and its CE-marked NEVAT m-TEVAR system, which could further broaden its product portfolio.
Artivion (AORT) Stock Forum and Discussion
This article provides a platform for discussion and a forum specifically dedicated to Artivion (AORT) stock. It likely serves as a community hub for investors and interested parties to share insights and opinions about the company's financial performance and future prospects.
Artivion (AORT) director receives 7,576-share equity grant, holds 46,960 shares
Anthony B. Semedo, a director at Artivion (AORT), received a grant of 7,576 shares of common stock as part of an equity award, with no cash payment per share. This award is scheduled to vest on May 18, 2027, under the company's Equity and Cash Incentive Plan. Following this transaction, Semedo directly holds 46,960 shares and indirectly owns an additional 600 shares through his spouse.
Artivion (AORT) director receives 7,576-share stock grant
Artivion (AORT) director Jeffrey H. Burbank was granted 7,576 shares of common stock at no purchase price on May 18, 2026, as part of the company's Equity and Cash Incentive Plan. These Restricted Stock Award (RSA) shares are scheduled to vest on May 18, 2027, and following this transaction, Burbank directly holds 61,372 shares of Artivion stock. This grant represents routine compensation rather than an open-market trade.
Artivion (AORT) director awarded 7,576 restricted common shares
Artivion (AORT) director Jon W. Salveson was awarded 7,576 restricted common shares as a stock grant, increasing his direct holdings to 137,416 shares. This award was granted at no cash cost and is scheduled to vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan. The transaction was reported on a Form 4 filed with the SEC, indicating a compensation-related acquisition rather than an open-market purchase.
Artivion (AORT) director receives 7,576-share equity award grant
Artivion (AORT) director Thomas F. Ackerman was granted 7,576 restricted shares of common stock on May 18, 2026, at no cash cost. These shares will vest on May 18, 2027, as per the company's Equity and Cash Incentive Plan. Following this award, Ackerman's direct holdings in Artivion now total 157,472 shares.
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System
Artivion has finalized its acquisition of Endospan Ltd., integrating the FDA-approved NEXUS Aortic Arch System into its product lineup. This strategic move aims to bolster Artivion's presence in the endovascular aortic repair market and complement its existing portfolio with next-generation aortic arch technologies. The deal involves an upfront payment of approximately $131.3 million and potential milestone payments up to $200 million.
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938
Artivion (AORT) Director Marna P. Borgstrom has received an equity compensation grant of 7,850 shares of Common Stock at a stated price of $0.00 per share, as reported in a Form 4 SEC filing. This award, part of the company's Equity and Cash Incentive Plan, increases her direct holdings to 56,938 shares. The RSA grant is scheduled to vest on May 14, 2027, aligning director compensation with the company's long-term performance.
Artivion closes Endospan buyout to acquire recently approved heart device
Artivion has finalized its acquisition of Endospan for an upfront payment of $131.3 million, securing the recently FDA-approved Nexus Aortic Arch System. The company plans to launch Nexus in the U.S. in January, targeting a $150 million annual market, and has identified around 100 high-volume accounts for initial sales. This acquisition strengthens Artivion's portfolio of treatments for aortic arch conditions.
Artivion secures FDA approval for NEXUS aortic arch system
Artivion, Inc. (AORT) announced that it has received FDA approval for its NEXUS Aortic Arch System, a significant milestone for the first and only de-branched stent graft designed for total aortic arch replacement. The company expects a limited market release of the new system in 2025, followed by a full market release in 2026. This approval positions Artivion to meet a major unmet clinical need and expand its market presence.
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition
Artivion has acquired Endospan in a $135 million upfront deal, exercising a license option following US FDA approval of Endospan's NEXUS aortic graft stent system. This acquisition, which includes potential additional payments up to $200 million based on commercial performance, significantly expands Artivion's aortic arch portfolio. The NEXUS system treats high-risk surgical patients with aortic arch disease, a condition affecting over 120,000 patients annually in the US and Europe.
